Compositions and in situ methods for forming films on body tissue

• US 5,081,158 A
• Filed: 03/08/1990
• Issued: 01/14/1992
• Est. Priority Date: 05/02/1988
• Status: Expired due to Term

• Current Assignee: Zila Pharmaceuticals Incorporated (TOLMAR Holding, Inc.)
• Original Assignee: Zila Pharmaceuticals Incorporated (TOLMAR Holding, Inc.)
• Inventors: Pomerantz, Edwin
• Primary Examiner(s): Griffin, Ronald W.
• Application Number:
  US07/474,743
• Time in Patent Office: 677 Days
• Field of Search: 514/414, 514/781, 514/925, 514/928, 424/434, 424/435, 424/488
• US Class Current: 514/781
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 31/69 Boron compounds
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 9/006 Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• CPC Class Codes: A61K 9/7015 Drug-containing film-forming compositions, e.g. spray-on
• CPC Class Codes: C09D 101/284 with hydroxylated hydrocarbon radicals

Abstract

Medicated protective films are formed in situ on body tissue by applying a composition comprising (a) hydroxypropyl cellulose; (b) an esterification agent which reacts with the hydroxypropyl cellulose to form a reaction product which is soluble in the solvent of (c), but insoluble in body fluids at body temperatures; and (c) a nontoxic volatile solvent for said hydroxypropyl cellulose and said reaction products; and (d) a separate medicinal component. The films are tough, resilient and adhesive to body tissue including the mucosa.

Claims

1. A liquid composition for in situ formation of medicament films on body tissue, comprising:

(a) 0.1 to 20 percent by weight of hydroxypropyl cellulose;

(b) an esterification agent which reacts with the hydroxypropyl cellulose to form a reaction product which is soluble in the solvent of paragraph (c), but insoluble in body fluids at body temperatures;

(c) a nontoxic volatile solvent for said hydroxypropyl cellulose and said reaction product; and

(d) a separate medicinal component in addition to said esterification agent.

2. The composition of claim 1 wherein the esterification agent is a weak organic acid.

3. The composition of claim 2 in which the esterification agent is salicylic acid.

4. The composition of claim 2 in which the esterification agent is a mixture of salicylic and tannic acid.

5. The composition of claim 4 in which the esterification agent further includes boric acid as a cross-linking agent.